|Bid||4.8200 x 1200|
|Ask||4.9500 x 3200|
|Day's Range||4.7700 - 5.2100|
|52 Week Range||1.8600 - 9.5400|
|Beta (5Y Monthly)||1.04|
|PE Ratio (TTM)||N/A|
|Earnings Date||Oct 27, 2021 - Nov 01, 2021|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||5.13|
Subscribe to Yahoo Finance Plus to view Fair Value for CRVSLearn more
The Zacks Analyst Blog Highlights: Condor Hospitality Trust, Corvus Pharmaceuticals, Covenant Logistics and Herc Holdings
The market remains on its toes as investors digest the ton of information hitting us about now.
Biotech stocks have been some of the most reliable capital-appreciation vehicles in the entire market for the past two decades. As proof, biotech equities such as CRISPR Therapeutics, Moderna, Novavax, Ocugen, and Vertex Pharmaceuticals -- just to name a few -- have all made their early shareholders market-crushing gains. Not all biotech stocks are cut from the same cloth, however.